A multicenter Spanish study of atropine 0.01% in childhood myopia progression

Abstract To evaluate the efficacy and safety of atropine 0.01% eye drops for myopia control in a multicentric pediatric Spanish cohort. An interventional, prospective, multicenter study was designed. Children aged between 6 and 14 years, with myopia between − 2.00 D to − 6.00 D, astigmatism < 1.5...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Inés Pérez-Flores, Beatríz Macías-Murelaga, Jesús Barrio-Barrio, Multicenter Group of Atropine Treatment for Myopia Control (GTAM)
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/32fe47381c1f4625a9f94472eca1c0f8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:32fe47381c1f4625a9f94472eca1c0f8
record_format	dspace
spelling	oai:doaj.org-article:32fe47381c1f4625a9f94472eca1c0f82021-11-08T10:46:57ZA multicenter Spanish study of atropine 0.01% in childhood myopia progression10.1038/s41598-021-00923-12045-2322https://doaj.org/article/32fe47381c1f4625a9f94472eca1c0f82021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-00923-1https://doaj.org/toc/2045-2322Abstract To evaluate the efficacy and safety of atropine 0.01% eye drops for myopia control in a multicentric pediatric Spanish cohort. An interventional, prospective, multicenter study was designed. Children aged between 6 and 14 years, with myopia between − 2.00 D to − 6.00 D, astigmatism < 1.50 D and documented previous annual progression greater than − 0.5 D (cycloplegic spherical equivalent, SE) were included. Once nightly atropine 0.01% eye drops in each eye were prescribed to all participants for 12 months. Age, gender, ethnicity and iris color were registered. All patients underwent the same follow-up protocol in every center: baseline visit, telephone consultation 2 weeks later and office controls at 4, 8 and 12 months. At each visit, best-corrected visual acuity, and cycloplegic autorefraction were assessed. Axial length (AL), anterior chamber depth and pupil diameter were measured on an IOL Master (Carl Zeiss Meditec, Inc, Dublin, CA). Adverse effects were registered in a specific questionnaire. Mean changes in cycloplegic SE and AL in the 12 months follow-up were analyzed. SE progression during treatment was compared with the SE progression in the year before enrollment for each patient. Correlation between SE and AL, and annual progression distribution were evaluated. Progression risk factors were analyzed by multivariate logistic regression analyses. Of the 105 recruited children, 92 completed the treatment. Mean SE and AL changes were − 0.44 ± 0.41 D and 0.27 ± 0.20 mm respectively. Mean SE progression was lower than the year before treatment (− 0.44 ± 0.41 D versus − 1.01 ± 0.38 D; p < 0.0001). An inverse correlation between SE progression and AL progression (r: − 0.42; p < 0.0001) was found. Fifty-seven patients (62%) had a SE progression less than − 0.50 D. No risk factors associated with progression could be identified in multivariate analyses. Mean pupil diameter increment at 12-months visit was 0.74 ± 1.76 mm. The adverse effects were mild and infrequent, and decreased over the time. Atropine 0.01% is effective and safe for myopia progression control in a multicentric Spanish children cohort. We believe this efficacy might be extensible to the myopic pediatric population from Western countries with similar social and demographic features. More studies about myopia progression risk factors among atropine treated patients are needed.Inés Pérez-FloresBeatríz Macías-MurelagaJesús Barrio-BarrioMulticenter Group of Atropine Treatment for Myopia Control (GTAM)Nature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Inés Pérez-Flores Beatríz Macías-Murelaga Jesús Barrio-Barrio Multicenter Group of Atropine Treatment for Myopia Control (GTAM) A multicenter Spanish study of atropine 0.01% in childhood myopia progression
description	Abstract To evaluate the efficacy and safety of atropine 0.01% eye drops for myopia control in a multicentric pediatric Spanish cohort. An interventional, prospective, multicenter study was designed. Children aged between 6 and 14 years, with myopia between − 2.00 D to − 6.00 D, astigmatism < 1.50 D and documented previous annual progression greater than − 0.5 D (cycloplegic spherical equivalent, SE) were included. Once nightly atropine 0.01% eye drops in each eye were prescribed to all participants for 12 months. Age, gender, ethnicity and iris color were registered. All patients underwent the same follow-up protocol in every center: baseline visit, telephone consultation 2 weeks later and office controls at 4, 8 and 12 months. At each visit, best-corrected visual acuity, and cycloplegic autorefraction were assessed. Axial length (AL), anterior chamber depth and pupil diameter were measured on an IOL Master (Carl Zeiss Meditec, Inc, Dublin, CA). Adverse effects were registered in a specific questionnaire. Mean changes in cycloplegic SE and AL in the 12 months follow-up were analyzed. SE progression during treatment was compared with the SE progression in the year before enrollment for each patient. Correlation between SE and AL, and annual progression distribution were evaluated. Progression risk factors were analyzed by multivariate logistic regression analyses. Of the 105 recruited children, 92 completed the treatment. Mean SE and AL changes were − 0.44 ± 0.41 D and 0.27 ± 0.20 mm respectively. Mean SE progression was lower than the year before treatment (− 0.44 ± 0.41 D versus − 1.01 ± 0.38 D; p < 0.0001). An inverse correlation between SE progression and AL progression (r: − 0.42; p < 0.0001) was found. Fifty-seven patients (62%) had a SE progression less than − 0.50 D. No risk factors associated with progression could be identified in multivariate analyses. Mean pupil diameter increment at 12-months visit was 0.74 ± 1.76 mm. The adverse effects were mild and infrequent, and decreased over the time. Atropine 0.01% is effective and safe for myopia progression control in a multicentric Spanish children cohort. We believe this efficacy might be extensible to the myopic pediatric population from Western countries with similar social and demographic features. More studies about myopia progression risk factors among atropine treated patients are needed.
format	article
author	Inés Pérez-Flores Beatríz Macías-Murelaga Jesús Barrio-Barrio Multicenter Group of Atropine Treatment for Myopia Control (GTAM)
author_facet	Inés Pérez-Flores Beatríz Macías-Murelaga Jesús Barrio-Barrio Multicenter Group of Atropine Treatment for Myopia Control (GTAM)
author_sort	Inés Pérez-Flores
title	A multicenter Spanish study of atropine 0.01% in childhood myopia progression
title_short	A multicenter Spanish study of atropine 0.01% in childhood myopia progression
title_full	A multicenter Spanish study of atropine 0.01% in childhood myopia progression
title_fullStr	A multicenter Spanish study of atropine 0.01% in childhood myopia progression
title_full_unstemmed	A multicenter Spanish study of atropine 0.01% in childhood myopia progression
title_sort	multicenter spanish study of atropine 0.01% in childhood myopia progression
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/32fe47381c1f4625a9f94472eca1c0f8
work_keys_str_mv	AT inesperezflores amulticenterspanishstudyofatropine001inchildhoodmyopiaprogression AT beatrizmaciasmurelaga amulticenterspanishstudyofatropine001inchildhoodmyopiaprogression AT jesusbarriobarrio amulticenterspanishstudyofatropine001inchildhoodmyopiaprogression AT multicentergroupofatropinetreatmentformyopiacontrolgtam amulticenterspanishstudyofatropine001inchildhoodmyopiaprogression AT inesperezflores multicenterspanishstudyofatropine001inchildhoodmyopiaprogression AT beatrizmaciasmurelaga multicenterspanishstudyofatropine001inchildhoodmyopiaprogression AT jesusbarriobarrio multicenterspanishstudyofatropine001inchildhoodmyopiaprogression AT multicentergroupofatropinetreatmentformyopiacontrolgtam multicenterspanishstudyofatropine001inchildhoodmyopiaprogression
_version_	1718442607362703360

A multicenter Spanish study of atropine 0.01% in childhood myopia progression

Ejemplares similares